Last edition
News about "Fenebrutinib "
Roche's Fenebrutinib Shows Promise in Third Phase III MS Trial
Roche reported positive Phase III FENhance 1 results, with fenebrutinib reducing relapses by 51 percent in relapsing multiple sclerosis, consistent with prior FENhance 2 and FENtrepid data. The company plans regulatory submissions, positioning fenebrutinib as a potential first-in-class BTK inhibitor for relapsing and primary progressive MS.
Fenebrutinib | 02/03/2026 | By News Bureau | 136
Roche reported positive late-breaking Phase III ACTRIMS data showing fenebrutinib reduced disability progression in Primary Progressive Multiple Sclerosis (PPMS), demonstrating non-inferiority to OCREVUS and reinforcing its potential as a first-in-class oral BTK inhibitor.
Fenebrutinib | 09/02/2026 | By News Bureau | 130
In the pivotal FENtrepid trial, Roche’s BTK inhibitor fenebrutinib demonstrated a meaningful reduction in disability progression in Primary Progressive Multiple Sclerosis (PPMS), performing at least on par with OCREVUS—the current standard and only approved treatment for PPMS.
Fenebrutinib | 15/11/2025 | By Dineshwori | 233
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy